Autologous hematopoietic stem cell transplantation for breast cancer in Europe: Critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999

Bone Marrow Transplantation

Volumn 32, Issue 5, 2003, Pages 489-494

  Pedrazzoli, P ^a   Ferrante, P ^b   Kulekci, A ^c   Schiavo, R ^a   De Giorgi, U ^b   Carminati, O ^a   Marangolo, M ^b   Demirer, T ^c   Siena, S ^a   Rosti, G ^b  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Ospedale Civile   (Italy)

^c ANKARA UNIVERSITY   (Turkey)

Author keywords

Breast cancer; High dose chemotherapy; Stem cell transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; MITOXANTRONE; THIOTEPA;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER REGISTRY; CANCER REGRESSION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DISEASE COURSE; DRUG MEGADOSE; EUROPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MASTITIS; METASTASIS; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; EUROPE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; REGISTRIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 10744224038     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704153     Document Type: Article

References (34)

1. Winer EC, Morrow M, Osborne CK, Harris JR. Malignant tumors of the breast. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds). Cancer: Principles and Practice of Oncology. Lippincott-Raven: Philadelphia, PA, 2001, pp. 1651-1716.
2. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with CR following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
3. Skipper HE. Dose intensity versus total dose of chemotherapy: an experimental basis. In: De Vita VT, Hellman S, Rosenberg SA (eds). Important Advances in Oncology. Lippincott-Raven: Philadelphia, PA, 1990, pp. 43-64.
4. Lazarus HM. Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. Cancer Invest 1998; 16: 102-126.
5. Crown J. High-dose chemotherapy of metastatic breast cancer: the end of the beginning? Br J Cancer 1997; 75: 467-479.
6. Gianni AM, Siena S, Bregni M et al. Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation. Lancet 1989; 2: 580-585.
7. Siena S, Bregni M, Brando B et al. Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose cyclophosphamide-treated patients: enhancement by intravenous recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1989; 74: 1905-1914.
8. Schmitz N, Linch DC, Dreger P et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
9. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
10. Neymark N, Rosti G: Patient management strategies and transplantation techniques in European stem cell transplantation centers offering breast cancer patients high-dose chemotherapy with peripheral blood stem cell support: a joint report from the EORTC and EBMT. Haematologica 2000; 85: 733-744.
11. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med 2000; 342: 1069-1076.
12. Crump M, Gluck S, Stewart D et al. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a National Cancer Institute of Canada (NCIC) Clinical Trials Group Study. J Clin Oncol 2001; 20: 21a (Abstr).
13. Bergh J, Wiklund T, Erikstein B et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 2000; 356: 1384-1391.
14. Peters W, Rosner G, Vrendeburgh J et al. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: CALBG 9082/SWOG 9114/NCIC Ma. 13. J Clin Oncol 2001; 20: 21a (Abstr).
15. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes. J Clin Oncol 2001; 20: 21a (Abstr).
16. Gianni L: High-dose chemotherapy for breast cancer: any use for it. Ann Oncol 2002; 13: 650-652.
17. Pedrazzoli P, Siena S. Clinical results in 2001 show high dose therapy and hematopoietic progenitor cell transplantation as a therapeutic option for breast cancer. Haematologica 2001; 86: 900-907.
18. Berry DA, Broadwater G, Klein JP et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry. J Clin Oncol 2002; 20: 743-750.
19. Gratwohl A, Hermans J. Bone marrow transplantation activity in Europe 1992: report from the European Group for Bone Marrow Transplantation (EBMT). Bone Marrow Transplant 1994; 13: 5-10.
20. Gratwohl A, Passweg J, Baldomero H, Urbano-Hispizua A. European Group for Blood and Marrow Transplantation (EBMT), hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 2001; 27: 899-916.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
22. Cox DR. Regression models and life tablets. J R Stat Soc B 1972; 3: 187-202.
23. Antman KH, Rowlings PA, Vaughn WP et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870-1879.
24. Siena S, Bregni M, Di Nicola M et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol 1994; 5: 935-941.
25. Stadtmauer EA, O'Neill A, Goldstein LJ et al. Conventional-dose chemotherapy with high-dose chemotherapy plus autologous stem cell transplantation for metastatic breast cancer: 5-year update of the Philadelphia trial. J Clin Oncol2002; 21: 43a (Abstr).
26. Rodenhuis S, Bontenbal M, Beex L et al. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. J Clin Oncol 2000; 19: 74a (Abstr).
27. Crown JP, Lind M, Gould A et al. High dose chemotherapy with autograft (PBP) support is not superior cyclophosphamide, methotrexare and FU following doxorubicin induction in patients with breast cancer and 4 or more involved axillary lymph nodes: the anglo-celtic I study. J Clin Oncol 2002; 21: 42a (Abstr).
28. Zander AR, Kruger W, Kroger N et al. High-dose chemotherapy with autologous hematopoietic stem-cell support (HSCS) vs. standard dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first result of a randomized trial. J Clin Oncol 2002; 21: 415a (Abstr).
29. Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10: 1014-1024.
30. Thomas F, Arriagada R, Spielmann M et al. Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. Cancer 1995; 76: 2286-2290.
31. Viens P, Penault-Llorca F, Jacquemier J et al. High-dose chemotherapy and haematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249-254.
32. Rowlings PA, Williams SF, Antman KH et al. Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA 1999; 282: 1335-1343.
33. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol 2002; 20: 620-623.
34. Lotz JP, Cure H, Janvier M et al. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: results of the French protocol PEGASE 04. J Clin Oncol 1999; 18: 43a (Abstr).